- Home
- TRAK vs CRDF Comparison
TRAK vs CRDF Comparison
Compare TRAK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRAK | CRDF |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.5M | 187.9M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRAK | CRDF |
|---|---|---|
| Price | $11.25 | $2.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 104.3K | ★ 869.1K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 19.98 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $23,136,391.00 | $501,000.00 |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $24.17 | N/A |
| P/E Ratio | $31.09 | ★ N/A |
| Revenue Growth | ★ 11.05 | N/A |
| 52 Week Low | $10.69 | $1.90 |
| 52 Week High | $23.72 | $4.99 |
Technical Indicators
Market Signals| Indicator | TRAK | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 57.56 |
| Support Level | $10.69 | $2.72 |
| Resistance Level | $12.15 | $3.02 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 28.97 | 52.10 |
Price Performance
Historical ComparisonAbout TRAK ReposiTrak Inc.
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.